Centiva Capital’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-1,700
Closed -$246K 1836
2024
Q4
$246K Sell
1,700
-75,600
-98% -$11.7M 0.01% 1256
2024
Q3
$12.5M Buy
77,300
+72,300
+1,446% +$11.5M 0.25% 68
2024
Q2
$731K Buy
5,000
+3,500
+233% +$521K 0.01% 941
2024
Q1
$237K Sell
1,500
-38,500
-96% -$6.13M 0.01% 1379
2023
Q4
$6.27M Hold
40,000
0.15% 121
2023
Q3
$6.23M Sell
40,000
-1,000
-2% -$165K 0.14% 129
2023
Q2
$6.79M Buy
41,000
+16,000
+64% +$2.58M 0.15% 122
2023
Q1
$3.88M Buy
25,000
+5,000
+25% +$807K 0.1% 230
2022
Q4
$3.53M Hold
20,000
0.1% 214
2022
Q3
$3.27M Buy
20,000
+15,000
+300% +$2.54M 0.06% 234
2022
Q2
$888K Sell
5,000
-5,000
-50% -$891K 0.02% 673
2022
Q1
$1.77M Buy
+10,000
New +$1.7M 0.03% 479
2021
Q1
Sell
-17,300
Closed -$2.72M 1280
2020
Q4
$2.72M Buy
+17,300
New +$2.55M 0.11% 114
2020
Q2
Sell
-300
Closed -$39K 743
2020
Q1
$39K Sell
300
-11,800
-98% -$1.67M ﹤0.01% 550
2019
Q4
$1.76M Buy
+12,100
New +$1.64M 0.09% 214
2018
Q3
Sell
-500
Closed -$61K 195
2018
Q2
$61K Buy
+500
New +$62.4K 0.01% 94

Other funds holding JNJ

Centiva Capital's JNJ Position: Q3 2025 in Review

Centiva Capital sold out of Johnson & Johnson (JNJ) in Q3 2025, closing a stake of 4,023 shares — an estimated $615K sold.

Centiva Capital first reported a position in JNJ in Q2 2018 and held it in 23 quarters. The position peaked at $11.5M in Q2 2020. 4,188 funds tracked by Wall St. Rank hold JNJ as of Q3 2025.

  • Centiva Capital reported no remaining Johnson & Johnson position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 4,023 Johnson & Johnson shares in Q3 2025, an estimated $615K.
  • Centiva Capital first reported a position in Johnson & Johnson in Q2 2018 and held it in 23 quarters.
  • Centiva Capital's Johnson & Johnson position peaked at $11.5M in Q2 2020.
  • 4,188 funds tracked by Wall St. Rank held Johnson & Johnson as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.